What's Happening?
Promega Corporation has introduced the TarSeer BRETSA Target Engagement System, a new live-cell target engagement platform, at the SLAS 2026 conference in Boston. This technology aims to bridge the gap between biochemical and cellular assays for proteins that are difficult to study. The system uses bioluminescence resonance energy transfer to detect ligand-protein interactions in intact cells, providing early, target-specific insights for drug discovery. This innovation allows researchers to study intracellular target engagement for a wide range of proteins, potentially expanding the scope of druggable targets in live-cell workflows.
Why It's Important?
The introduction of the TarSeer BRETSA system represents a significant advancement in drug discovery, particularly
for proteins that have been challenging to target. By enabling early cellular characterization of target-ligand interactions, the technology reduces uncertainty in compound prioritization and enhances confidence in early-stage drug development. This could accelerate the discovery of new therapeutics, benefiting pharmaceutical companies and ultimately patients. The system's ability to address previously intractable targets could lead to breakthroughs in treating diseases with unmet medical needs.
What's Next?
Promega plans to showcase the capabilities of the TarSeer BRETSA system at the SLAS 2026 conference, with presentations and discussions on its applications across various target classes. The company will continue to support researchers in developing small molecule drugs against a wide range of disease-relevant proteins. As the technology gains traction, it may lead to collaborations with pharmaceutical companies seeking to enhance their drug discovery pipelines. The broader adoption of this platform could drive innovation in the life sciences industry, potentially leading to new therapeutic options.
